home / stock / sgmo / sgmo news

SGMO News and Press, Sangamo Therapeutics Inc. From 03/06/24

Stock Information
Company Name: Sangamo Therapeutics Inc.
Stock Symbol: SGMO
Market: NASDAQ
Website: sangamo.com
Menu
SGMO SGMO Quote SGMO Short SGMO News SGMO Articles SGMO Message Board
Get SGMO Alerts

News, Short Squeeze, Breakout and More Instantly...
SGMO - Expected US Company Earnings on Wednesday, March 6th, 2024

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
SGMO - Expected US Company Earnings on Wednesday, February 28th, 2024

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

SGMO - US Companies Moving the Markets, Evening edition
Mon, Feb 12, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Beamr Imaging Ltd. (BMR) rose 687.2% to $16.61 on volume of 140,756,692 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.0% to $4.3084 on volume of 120,282,414 shares Arm Holdings plc (ARM) rose 26.0% to $145.1201 on v...

SGMO - Sangamo stock soars 37% on updates for Fabry disease therapy

2024-02-12 13:29:17 ET More on Sangamo Therapeutics Seeking Alpha’s Quant Rating on Sangamo Therapeutics Historical earnings data for Sangamo Therapeutics Financial information for Sangamo Therapeutics Read the full article on Seeking Alpha For...
SGMO - Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA) submission for isaralgagene civaparvovec, which would significantly reduce anticipated comple...

SGMO - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

- Sustained elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for up to three years for the longest-treated patient as of the data cutoff date. - All 12 patients withdrawn from enzyme replacement therapy (ERT) remain off ERT, with sustained elevated ...

SGMO - Gene editing stocks slide after two-day rally

2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...
SGMO - Wells Fargo downgrades Sangamo, cites removal of key year-end catalyst

2023-11-06 14:45:28 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript Sangamo Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction ...

SGMO - RBC Capital downgrades Sangamo as biotech moves to save cash

2023-11-03 15:32:03 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript Sangamo Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction ...

SGMO - Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript

2023-11-02 11:51:04 ET Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Louise Wilkie - Vice President-Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathal...
Previous 10 Next 10